Melbourne School of Population and Global Health - Research Publications

Permanent URI for this collection

Search Results

Now showing 1 - 10 of 13
  • Item
    No Preview Available
    Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study
    Dixon-Suen, SC ; Lewis, SJ ; Martin, RM ; English, DR ; Boyle, T ; Giles, GG ; Michailidou, K ; Bolla, MK ; Wang, Q ; Dennis, J ; Lush, M ; Ahearn, TU ; Ambrosone, CB ; Andrulis, IL ; Anton-Culver, H ; Arndt, V ; Aronson, KJ ; Augustinsson, A ; Auvinen, P ; Beane Freeman, LE ; Becher, H ; Beckmann, MW ; Behrens, S ; Bermisheva, M ; Blomqvist, C ; Bogdanova, N ; Bojesen, SE ; Bonanni, B ; Brenner, H ; Bruening, T ; Buys, SS ; Camp, NJ ; Campa, D ; Canzian, F ; Castelao, JE ; Cessna, MH ; Chang-Claude, J ; Chanock, SJ ; Clarke, CL ; Conroy, DM ; Couch, FJ ; Cox, A ; Cross, SS ; Czene, K ; Daly, MB ; Devilee, P ; Doerk, T ; Dwek, M ; Eccles, DM ; Eliassen, AH ; Engel, C ; Eriksson, M ; Evans, DG ; Fasching, PA ; Fletcher, O ; Flyger, H ; Fritschi, L ; Gabrielson, M ; Gago-Dominguez, M ; Garcia-Closas, M ; Garcia-Saenz, JA ; Goldberg, MS ; Guenel, P ; Guendert, M ; Hahnen, E ; Haiman, CA ; Haeberle, L ; Hakansson, N ; Hall, P ; Hamann, U ; Hart, SN ; Harvie, M ; Hillemanns, P ; Hollestelle, A ; Hooning, MJ ; Hoppe, R ; Hopper, J ; Howell, A ; Hunter, DJ ; Jakubowska, A ; Janni, W ; John, EM ; Jung, A ; Kaaks, R ; Keeman, R ; Kitahara, CM ; Koutros, S ; Kraft, P ; Kristensen, VN ; Kubelka-Sabit, K ; Kurian, AW ; Lacey, J ; Lambrechts, D ; Le Marchand, L ; Lindblom, A ; Loibl, S ; Lubinski, J ; Mannermaa, A ; Manoochehri, M ; Margolin, S ; Martinez, ME ; Mavroudis, D ; Menon, U ; Mulligan, AM ; Murphy, RA ; Nevanlinna, H ; Nevelsteen, I ; Newman, WG ; Offit, K ; Olshan, AF ; Olsson, H ; Orr, N ; Patel, A ; Peto, J ; Plaseska-Karanfilska, D ; Presneau, N ; Rack, B ; Radice, P ; Rees-Punia, E ; Rennert, G ; Rennert, HS ; Romero, A ; Saloustros, E ; Sandler, DP ; Schmidt, MK ; Schmutzler, RK ; Schwentner, L ; Scott, C ; Shah, M ; Shu, X-O ; Simard, J ; Southey, MC ; Stone, J ; Surowy, H ; Swerdlow, AJ ; Tamimi, RM ; Tapper, WJ ; Taylor, JA ; Terry, MB ; Tollenaar, RAEM ; Troester, MA ; Truong, T ; Untch, M ; Vachon, CM ; Joseph, V ; Wappenschmidt, B ; Weinberg, CR ; Wolk, A ; Yannoukakos, D ; Zheng, W ; Ziogas, A ; Dunning, AM ; Pharoah, PDP ; Easton, DF ; Milne, RL ; Lynch, BM (BMJ PUBLISHING GROUP, 2022-10)
    OBJECTIVES: Physical inactivity and sedentary behaviour are associated with higher breast cancer risk in observational studies, but ascribing causality is difficult. Mendelian randomisation (MR) assesses causality by simulating randomised trial groups using genotype. We assessed whether lifelong physical activity or sedentary time, assessed using genotype, may be causally associated with breast cancer risk overall, pre/post-menopause, and by case-groups defined by tumour characteristics. METHODS: We performed two-sample inverse-variance-weighted MR using individual-level Breast Cancer Association Consortium case-control data from 130 957 European-ancestry women (69 838 invasive cases), and published UK Biobank data (n=91 105-377 234). Genetic instruments were single nucleotide polymorphisms (SNPs) associated in UK Biobank with wrist-worn accelerometer-measured overall physical activity (nsnps=5) or sedentary time (nsnps=6), or accelerometer-measured (nsnps=1) or self-reported (nsnps=5) vigorous physical activity. RESULTS: Greater genetically-predicted overall activity was associated with lower breast cancer overall risk (OR=0.59; 95% confidence interval (CI) 0.42 to 0.83 per-standard deviation (SD;~8 milligravities acceleration)) and for most case-groups. Genetically-predicted vigorous activity was associated with lower risk of pre/perimenopausal breast cancer (OR=0.62; 95% CI 0.45 to 0.87,≥3 vs. 0 self-reported days/week), with consistent estimates for most case-groups. Greater genetically-predicted sedentary time was associated with higher hormone-receptor-negative tumour risk (OR=1.77; 95% CI 1.07 to 2.92 per-SD (~7% time spent sedentary)), with elevated estimates for most case-groups. Results were robust to sensitivity analyses examining pleiotropy (including weighted-median-MR, MR-Egger). CONCLUSION: Our study provides strong evidence that greater overall physical activity, greater vigorous activity, and lower sedentary time are likely to reduce breast cancer risk. More widespread adoption of active lifestyles may reduce the burden from the most common cancer in women.
  • Item
    No Preview Available
    Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes: Pooled Analysis of Population-Based Studies
    Jung, AY ; Ahearn, TU ; Behrens, S ; Middha, P ; Bolla, MK ; Wang, Q ; Arndt, V ; Aronson, KJ ; Augustinsson, A ; Freeman, LEB ; Becher, H ; Brenner, H ; Canzian, F ; Carey, LA ; Consortium, C ; Czene, K ; Eliassen, AH ; Eriksson, M ; Evans, DG ; Figueroa, JD ; Fritschi, L ; Gabrielson, M ; Giles, GG ; Guenel, P ; Hadjisavvas, A ; Haiman, CA ; Hakansson, N ; Hall, P ; Hamann, U ; Hoppe, R ; Hopper, JL ; Howell, A ; Hunter, DJ ; Huesing, A ; Kaaks, R ; Kosma, V-M ; Koutros, S ; Kraft, P ; Lacey, J ; Le Marchand, L ; Lissowska, J ; Loizidou, MA ; Mannermaa, A ; Maurer, T ; Murphy, RA ; Olshan, AF ; Olsson, H ; Patel, A ; Perou, CM ; Rennert, G ; Shibli, R ; Shu, X-O ; Southey, MC ; Stone, J ; Tamimi, RM ; Teras, LR ; Troester, MA ; Truong, T ; Vachon, CM ; Wang, SS ; Wolk, A ; Wu, AH ; Yang, XR ; Zheng, W ; Dunning, AM ; Pharoah, PDP ; Easton, DF ; Milne, RL ; Chatterjee, N ; Schmidt, MK ; Garcia-Closas, M ; Chang-Claude, J (OXFORD UNIV PRESS INC, 2022-12)
    BACKGROUND: Reproductive factors have been shown to be differentially associated with risk of estrogen receptor (ER)-positive and ER-negative breast cancer. However, their associations with intrinsic-like subtypes are less clear. METHODS: Analyses included up to 23 353 cases and 71 072 controls pooled from 31 population-based case-control or cohort studies in the Breast Cancer Association Consortium across 16 countries on 4 continents. Polytomous logistic regression was used to estimate the association between reproductive factors and risk of breast cancer by intrinsic-like subtypes (luminal A-like, luminal B-like, luminal B-HER2-like, HER2-enriched-like, and triple-negative breast cancer) and by invasiveness. All statistical tests were 2-sided. RESULTS: Compared with nulliparous women, parous women had a lower risk of luminal A-like, luminal B-like, luminal B-HER2-like, and HER2-enriched-like disease. This association was apparent only after approximately 10 years since last birth and became stronger with increasing time (odds ratio [OR] = 0.59, 95% confidence interval [CI] = 0.49 to 0.71; and OR = 0.36, 95% CI = 0.28 to 0.46 for multiparous women with luminal A-like tumors 20 to less than 25 years after last birth and 45 to less than 50 years after last birth, respectively). In contrast, parous women had a higher risk of triple-negative breast cancer right after their last birth (for multiparous women: OR = 3.12, 95% CI = 2.02 to 4.83) that was attenuated with time but persisted for decades (OR = 1.03, 95% CI = 0.79 to 1.34, for multiparous women 25 to less than 30 years after last birth). Older age at first birth (Pheterogeneity < .001 for triple-negative compared with luminal A-like breast cancer) and breastfeeding (Pheterogeneity < .001 for triple-negative compared with luminal A-like breast cancer) were associated with lower risk of triple-negative breast cancer but not with other disease subtypes. Younger age at menarche was associated with higher risk of all subtypes; older age at menopause was associated with higher risk of luminal A-like but not triple-negative breast cancer. Associations for in situ tumors were similar to luminal A-like. CONCLUSIONS: This large and comprehensive study demonstrates a distinct reproductive risk factor profile for triple-negative breast cancer compared with other subtypes, with implications for the understanding of disease etiology and risk prediction.
  • Item
    Thumbnail Image
    Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci
    Chen, H ; Fan, S ; Stone, J ; Thompson, DJ ; Douglas, J ; Li, S ; Scott, C ; Bolla, MK ; Wang, Q ; Dennis, J ; Michailidou, K ; Li, C ; Peters, U ; Hopper, JL ; Southey, MC ; Nguyen-Dumont, T ; Nguyen, TL ; Fasching, PA ; Behrens, A ; Cadby, G ; Murphy, RA ; Aronson, K ; Howell, A ; Astley, S ; Couch, F ; Olson, J ; Milne, RL ; Giles, GG ; Haiman, CA ; Maskarinec, G ; Winham, S ; John, EM ; Kurian, A ; Eliassen, H ; Andrulis, I ; Evans, DG ; Newman, WG ; Hall, P ; Czene, K ; Swerdlow, A ; Jones, M ; Pollan, M ; Fernandez-Navarro, P ; McConnell, DS ; Kristensen, VN ; Rothstein, JH ; Wang, P ; Habel, LA ; Sieh, W ; Dunning, AM ; Pharoah, PDP ; Easton, DF ; Gierach, GL ; Tamimi, RM ; Vachon, CM ; Lindstrom, S (BMC, 2022-04-12)
    BACKGROUND: Mammographic density (MD) phenotypes, including percent density (PMD), area of dense tissue (DA), and area of non-dense tissue (NDA), are associated with breast cancer risk. Twin studies suggest that MD phenotypes are highly heritable. However, only a small proportion of their variance is explained by identified genetic variants. METHODS: We conducted a genome-wide association study, as well as a transcriptome-wide association study (TWAS), of age- and BMI-adjusted DA, NDA, and PMD in up to 27,900 European-ancestry women from the MODE/BCAC consortia. RESULTS: We identified 28 genome-wide significant loci for MD phenotypes, including nine novel signals (5q11.2, 5q14.1, 5q31.1, 5q33.3, 5q35.1, 7p11.2, 8q24.13, 12p11.2, 16q12.2). Further, 45% of all known breast cancer SNPs were associated with at least one MD phenotype at p < 0.05. TWAS further identified two novel genes (SHOX2 and CRISPLD2) whose genetically predicted expression was significantly associated with MD phenotypes. CONCLUSIONS: Our findings provided novel insight into the genetic background of MD phenotypes, and further demonstrated their shared genetic basis with breast cancer.
  • Item
    Thumbnail Image
    Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment
    Morra, A ; Escala-Garcia, M ; Beesley, J ; Keeman, R ; Canisius, S ; Ahearn, TU ; Andrulis, IL ; Anton-Culver, H ; Arndt, V ; Auer, PL ; Augustinsson, A ; Freeman, LEB ; Becher, H ; Beckmann, MW ; Behrens, S ; Bojesen, SE ; Bolla, MK ; Brenner, H ; Bruening, T ; Buys, SS ; Caan, B ; Campa, D ; Canzian, F ; Castelao, JE ; Chang-Claude, J ; Chanock, SJ ; Cheng, T-YD ; Clarke, CL ; Colonna, S ; Couch, FJ ; Cox, A ; Cross, SS ; Czene, K ; Daly, MB ; Dennis, J ; Dork, T ; Dossus, L ; Dunning, AM ; Dwek, M ; Eccles, DM ; Ekici, AB ; Eliassen, AH ; Eriksson, M ; Evans, DG ; Fasching, PA ; Flyger, H ; Fritschi, L ; Gago-Dominguez, M ; Garcia-Saenz, JA ; Giles, GG ; Grip, M ; Guenel, P ; Guendert, M ; Hahnen, E ; Haiman, CA ; Hakansson, N ; Hall, P ; Hamann, U ; Hart, SN ; Hartikainen, JM ; Hartmann, A ; He, W ; Hooning, MJ ; Hoppe, R ; Hopper, JL ; Howell, A ; Hunter, DJ ; Jager, A ; Jakubowska, A ; Janni, W ; John, EM ; Jung, AY ; Kaaks, R ; Keupers, M ; Kitahara, CM ; Koutros, S ; Kraft, P ; Kristensen, VN ; Kurian, AW ; Lacey, J ; Lambrechts, D ; Le Marchand, L ; Lindblom, A ; Linet, M ; Luben, RN ; Lush, M ; Mannermaa, A ; Manoochehri, M ; Margolin, S ; Martens, JWM ; Martinez, ME ; Mavroudis, D ; Michailidou, K ; Milne, RL ; Mulligan, AM ; Muranen, TA ; Nevanlinna, H ; Newman, WG ; Nielsen, SF ; Nordestgaard, BG ; Olshan, AF ; Olsson, H ; Orr, N ; Park-Simon, T-W ; Patel, A ; Peissel, B ; Peterlongo, P ; Plaseska-Karanfilska, D ; Prajzendanc, K ; Prentice, R ; Presneau, N ; Rack, B ; Rennert, G ; Rennert, HS ; Rhenius, V ; Romero, A ; Roylance, R ; Lubinski, J ; Ruebner, M ; Saloustros, E ; Sawyer, EJ ; Schmutzler, RK ; Schneeweiss, A ; Scott, C ; Shah, M ; Smichkoska, S ; Southey, MC ; Stone, J ; Surowy, H ; Swerdlow, AJ ; Tamimi, RM ; Tapper, WJ ; Teras, LR ; Terry, MB ; Tollenaar, RAEM ; Tomlinson, I ; Troester, MA ; Truong, T ; Vachon, CM ; Wang, Q ; Hurson, AN ; Winqvist, R ; Wolk, A ; Ziogas, A ; Brauch, H ; Garcia-Closas, M ; Pharoah, PDP ; Easton, DF ; Chenevix-Trench, G ; Schmidt, MK (BMC, 2021-08-18)
    BACKGROUND: Given the high heterogeneity among breast tumors, associations between common germline genetic variants and survival that may exist within specific subgroups could go undetected in an unstratified set of breast cancer patients. METHODS: We performed genome-wide association analyses within 15 subgroups of breast cancer patients based on prognostic factors, including hormone receptors, tumor grade, age, and type of systemic treatment. Analyses were based on 91,686 female patients of European ancestry from the Breast Cancer Association Consortium, including 7531 breast cancer-specific deaths over a median follow-up of 8.1 years. Cox regression was used to assess associations of common germline variants with 15-year and 5-year breast cancer-specific survival. We assessed the probability of these associations being true positives via the Bayesian false discovery probability (BFDP < 0.15). RESULTS: Evidence of associations with breast cancer-specific survival was observed in three patient subgroups, with variant rs5934618 in patients with grade 3 tumors (15-year-hazard ratio (HR) [95% confidence interval (CI)] 1.32 [1.20, 1.45], P = 1.4E-08, BFDP = 0.01, per G allele); variant rs4679741 in patients with ER-positive tumors treated with endocrine therapy (15-year-HR [95% CI] 1.18 [1.11, 1.26], P = 1.6E-07, BFDP = 0.09, per G allele); variants rs1106333 (15-year-HR [95% CI] 1.68 [1.39,2.03], P = 5.6E-08, BFDP = 0.12, per A allele) and rs78754389 (5-year-HR [95% CI] 1.79 [1.46,2.20], P = 1.7E-08, BFDP = 0.07, per A allele), in patients with ER-negative tumors treated with chemotherapy. CONCLUSIONS: We found evidence of four loci associated with breast cancer-specific survival within three patient subgroups. There was limited evidence for the existence of associations in other patient subgroups. However, the power for many subgroups is limited due to the low number of events. Even so, our results suggest that the impact of common germline genetic variants on breast cancer-specific survival might be limited.
  • Item
    No Preview Available
    Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses
    Zhan, H ; Ahearn, TU ; Lecarpentier, J ; Barnes, D ; Beesley, J ; Qi, G ; Jiang, X ; O'Mara, TA ; Zhao, N ; Bolla, MK ; Dunning, AM ; Dennis, J ; Wang, Q ; Abu Ful, Z ; Aittomaki, K ; Andrulis, IL ; Anton-Culver, H ; Arndt, V ; Aronson, KJ ; Arun, BK ; Auer, PL ; Azzollini, J ; Barrowdale, D ; Becher, H ; Beckmann, MW ; Behrens, S ; Benitez, J ; Bermisheva, M ; Bialkowska, K ; Blanco, A ; Blomqvist, C ; Bogdanova, N ; Bojesen, SE ; Bonanni, B ; Bondavalli, D ; Borg, A ; Brauch, H ; Brenner, H ; Briceno, I ; Broeks, A ; Brucker, SY ; Bruening, T ; Burwinkel, B ; Buys, SS ; Byers, H ; Caldes, T ; Caligo, MA ; Calvello, M ; Campa, D ; Castelao, JE ; Chang-Claude, J ; Chanock, SJ ; Christiaens, M ; Christiansen, H ; Chung, WK ; Claes, KBM ; Clarke, CL ; Cornelissen, S ; Couch, FJ ; Cox, A ; Cross, SS ; Czene, K ; Daly, MB ; Devilee, P ; Diez, O ; Domchek, SM ; Doerk, T ; Dwek, M ; Eccles, DM ; Ekici, AB ; Evans, DG ; Fasching, PA ; Figueroa, J ; Foretova, L ; Fostira, F ; Friedman, E ; Frost, D ; Gago-Dominguez, M ; Gapstur, SM ; Garber, J ; Garcia-Saenz, JA ; Gaudet, MM ; Gayther, SA ; Giles, GG ; Godwin, AK ; Goldberg, MS ; Goldgar, DE ; Gonzalez-Neira, A ; Greene, MH ; Gronwald, J ; Guenel, P ; Haeberle, L ; Hahnen, E ; Haiman, CA ; Hake, CR ; Hall, P ; Hamann, U ; Harkness, EF ; Heemskerk-Gerritsen, BAM ; Hillemanns, P ; Hogervorst, FBL ; Holleczek, B ; Hollestelle, A ; Hooning, MJ ; Hoover, RN ; Hopper, JL ; Howell, A ; Huebner, H ; Hulick, PJ ; Imyanitov, EN ; Isaacs, C ; Izatt, L ; Jager, A ; Jakimovska, M ; Jakubowska, A ; James, P ; Janavicius, R ; Janni, W ; John, EM ; Jones, ME ; Jung, A ; Kaaks, R ; Kapoor, PM ; Karlan, BY ; Keeman, R ; Khan, S ; Khusnutdinova, E ; Kitahara, CM ; Ko, Y-D ; Konstantopoulou, I ; Koppert, LB ; Koutros, S ; Kristensen, VN ; Laenkholm, A-V ; Lambrechts, D ; Larsson, SC ; Laurent-Puig, P ; Lazaro, C ; Lazarova, E ; Lejbkowicz, F ; Leslie, G ; Lesueur, F ; Lindblom, A ; Lissowska, J ; Lo, W-Y ; Loud, JT ; Lubinski, J ; Lukomska, A ; MacInnis, RJ ; Mannermaa, A ; Manoochehri, M ; Manoukian, S ; Margolin, S ; Martinez, ME ; Matricardi, L ; McGuffog, L ; McLean, C ; Mebirouk, N ; Meindl, A ; Menon, U ; Miller, A ; Mingazheva, E ; Montagna, M ; Mulligan, AM ; Mulot, C ; Muranen, TA ; Nathanson, KL ; Neuhausen, SL ; Nevanlinna, H ; Neven, P ; Newman, WG ; Nielsens, FC ; Nikitina-Zake, L ; Nodora, J ; Offit, K ; Olah, E ; Olopade, O ; Olsson, H ; Orr, N ; Papi, L ; Papp, J ; Park-Simon, T-W ; Parsons, MT ; Peissel, B ; Peixoto, A ; Peshkin, B ; Peterlongo, P ; Peto, J ; Phillips, K-A ; Piedmonte, M ; Plaseska-Karanfilska, D ; Prajzendanc, K ; Prentice, R ; Prokofyeva, D ; Rack, B ; Radice, P ; Ramus, SJ ; Rantala, J ; Rashid, MU ; Rennert, G ; Rennert, HS ; Risch, HA ; Romero, A ; Rookus, MA ; Ruebner, M ; Ruediger, T ; Saloustros, E ; Sampson, S ; Sandler, DP ; Sawyer, EJ ; Scheuner, MT ; Schmutzler, RK ; Schneeweiss, A ; Schoemaker, MJ ; Schoettker, B ; Schuermann, P ; Senter, L ; Sharma, P ; Sherman, ME ; Shu, X-O ; Singer, CF ; Smichkoska, S ; Soucy, P ; Southey, MC ; Spinelli, JJ ; Stone, J ; Stoppa-Lyonnet, D ; Swerdlow, AJ ; Szabo, C ; Tamimi, RM ; Tapper, WJ ; Taylor, JA ; Teixeira, MR ; Terry, M ; Thomassen, M ; Thull, DL ; Tischkowitz, M ; Toland, AE ; Tollenaar, RAEM ; Tomlinson, I ; Torres, D ; Troester, MA ; Truong, T ; Tung, N ; Untch, M ; Vachon, CM ; van den Ouweland, AMW ; van der Kolk, LE ; van Veen, EM ; vanRensburg, EJ ; Vega, A ; Wappenschmidt, B ; Weinberg, CR ; Weitzel, JN ; Wildiers, H ; Winqvist, R ; Wolk, A ; Yang, XR ; Yannoukakos, D ; Zheng, W ; Zorn, KK ; Milne, RL ; Kraft, P ; Simard, J ; Pharoah, PDP ; Michailidou, K ; Antoniou, AC ; Schmidt, MK ; Chenevix-Trench, G ; Easton, DF ; Chatterjee, N ; Garcia-Closas, M (NATURE RESEARCH, 2020-06)
    Breast cancer susceptibility variants frequently show heterogeneity in associations by tumor subtype1-3. To identify novel loci, we performed a genome-wide association study including 133,384 breast cancer cases and 113,789 controls, plus 18,908 BRCA1 mutation carriers (9,414 with breast cancer) of European ancestry, using both standard and novel methodologies that account for underlying tumor heterogeneity by estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status and tumor grade. We identified 32 novel susceptibility loci (P < 5.0 × 10-8), 15 of which showed evidence for associations with at least one tumor feature (false discovery rate < 0.05). Five loci showed associations (P < 0.05) in opposite directions between luminal and non-luminal subtypes. In silico analyses showed that these five loci contained cell-specific enhancers that differed between normal luminal and basal mammary cells. The genetic correlations between five intrinsic-like subtypes ranged from 0.35 to 0.80. The proportion of genome-wide chip heritability explained by all known susceptibility loci was 54.2% for luminal A-like disease and 37.6% for triple-negative disease. The odds ratios of polygenic risk scores, which included 330 variants, for the highest 1% of quantiles compared with middle quantiles were 5.63 and 3.02 for luminal A-like and triple-negative disease, respectively. These findings provide an improved understanding of genetic predisposition to breast cancer subtypes and will inform the development of subtype-specific polygenic risk scores.
  • Item
    Thumbnail Image
    Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element
    Baxter, JS ; Johnson, N ; Tomczyk, K ; Gillespie, A ; Maguire, S ; Brough, R ; Fachal, L ; Michailidou, K ; Bolla, MK ; Wang, Q ; Dennis, J ; Ahearn, TU ; Andrulis, IL ; Anton-Culver, H ; Antonenkova, NN ; Arndt, V ; Aronson, KJ ; Augustinsson, A ; Becher, H ; Beckmann, MW ; Behrens, S ; Benitez, J ; Bermisheva, M ; Bogdanova, N ; Bojesen, SE ; Brenner, H ; Brucker, SY ; Cai, Q ; Campa, D ; Canzian, F ; Castelao, JE ; Chan, TL ; Chang-Claude, J ; Chanock, SJ ; Chenevix-Trench, G ; Choi, J-Y ; Clarke, CL ; Collaborators, N ; Colonna, S ; Conroy, DM ; Couch, FJ ; Cox, A ; Cross, SS ; Czene, K ; Daly, MB ; Devilee, P ; Doerk, T ; Dossus, L ; Dwek, M ; Eccles, DM ; Ekici, AB ; Eliassen, AH ; Engel, C ; Fasching, PA ; Figueroa, J ; Flyger, H ; Gago-Dominguez, M ; Gao, C ; Garcia-Closas, M ; Garcia-Saenz, JA ; Ghoussaini, M ; Giles, GG ; Goldberg, MS ; Gonzalez-Neira, A ; Guenel, P ; Guendert, M ; Haeberle, L ; Hahnen, E ; Haiman, CA ; Hall, P ; Hamann, U ; Hartman, M ; Hatse, S ; Hauke, J ; Hollestelle, A ; Hoppe, R ; Hopper, JL ; Hou, M-F ; Ito, H ; Iwasaki, M ; Jager, A ; Jakubowska, A ; Janni, W ; John, EM ; Joseph, V ; Jung, A ; Kaaks, R ; Kang, D ; Keeman, R ; Khusnutdinova, E ; Kim, S-W ; Kosma, V-M ; Kraft, P ; Kristensen, VN ; Kubelka-Sabit, K ; Kurian, AW ; Kwong, A ; Lacey, J ; Lambrechts, D ; Larson, NL ; Larsson, SC ; Le Marchand, L ; Lejbkowicz, F ; Li, J ; Long, J ; Lophatananon, A ; LubiNski, J ; Mannermaa, A ; Manoochehri, M ; Manoukian, S ; Margolin, S ; Matsuo, K ; Mavroudis, D ; Mayes, R ; Menon, U ; Milne, RL ; Taib, NAM ; Muir, K ; Muranen, TA ; Murphy, RA ; Nevanlinna, H ; O'Brien, KM ; Offit, K ; Olson, JE ; Olsson, H ; Park, SK ; Park-Simon, T-W ; Patel, A ; Peterlongo, P ; Peto, J ; Plaseska-Karanfilska, D ; Presneau, N ; Pylkas, K ; Rack, B ; Rennert, G ; Romero, A ; Ruebner, M ; Ruediger, T ; Saloustros, E ; Sandler, DP ; Sawyer, EJ ; Schmidt, MK ; Schmutzler, RK ; Schneeweiss, A ; Schoemaker, MJ ; Shah, M ; Shen, C-Y ; Shu, X-O ; Simard, J ; Southey, MC ; Stone, J ; Surowy, H ; Swerdlow, AJ ; Tamimi, RM ; Tapper, WJ ; Taylor, JA ; Teo, SH ; Teras, LR ; Terry, MB ; Toland, AE ; Tomlinson, I ; Truong, T ; Tseng, C-C ; Untch, M ; Vachon, CM ; van den Ouweland, AMW ; Wang, SS ; Weinberg, CR ; Wendt, C ; Winham, SJ ; Winqvist, R ; Wolk, A ; Wu, AH ; Yamaji, T ; Zheng, W ; Ziogas, A ; Pharoah, PDP ; Dunning, AM ; Easton, DF ; Pettitt, SJ ; Lord, CJ ; Haider, S ; Orr, N ; Fletcher, O (CELL PRESS, 2021-07-01)
    A combination of genetic and functional approaches has identified three independent breast cancer risk loci at 2q35. A recent fine-scale mapping analysis to refine these associations resulted in 1 (signal 1), 5 (signal 2), and 42 (signal 3) credible causal variants at these loci. We used publicly available in silico DNase I and ChIP-seq data with in vitro reporter gene and CRISPR assays to annotate signals 2 and 3. We identified putative regulatory elements that enhanced cell-type-specific transcription from the IGFBP5 promoter at both signals (30- to 40-fold increased expression by the putative regulatory element at signal 2, 2- to 3-fold by the putative regulatory element at signal 3). We further identified one of the five credible causal variants at signal 2, a 1.4 kb deletion (esv3594306), as the likely causal variant; the deletion allele of this variant was associated with an average additional increase in IGFBP5 expression of 1.3-fold (MCF-7) and 2.2-fold (T-47D). We propose a model in which the deletion allele of esv3594306 juxtaposes two transcription factor binding regions (annotated by estrogen receptor alpha ChIP-seq peaks) to generate a single extended regulatory element. This regulatory element increases cell-type-specific expression of the tumor suppressor gene IGFBP5 and, thereby, reduces risk of estrogen receptor-positive breast cancer (odds ratio = 0.77, 95% CI 0.74-0.81, p = 3.1 × 10-31).
  • Item
    Thumbnail Image
    CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers
    Johnson, N ; Maguire, S ; Morra, A ; Kapoor, PM ; Tomczyk, K ; Jones, ME ; Schoemaker, MJ ; Gilham, C ; Bolla, MK ; Wang, Q ; Dennis, J ; Ahearn, TU ; Andrulis, IL ; Anton-Culver, H ; Antonenkova, NN ; Arndt, V ; Aronson, KJ ; Augustinsson, A ; Baynes, C ; Freeman, LEB ; Beckmann, MW ; Benitez, J ; Bermisheva, M ; Blomqvist, C ; Boeckx, B ; Bogdanova, NV ; Bojesen, SE ; Brauch, H ; Brenner, H ; Burwinkel, B ; Campa, D ; Canzian, F ; Castelao, JE ; Chanock, SJ ; Chenevix-Trench, G ; Clarke, CL ; Conroy, DM ; Couch, FJ ; Cox, A ; Cross, SS ; Czene, K ; Doerk, T ; Eliassen, AH ; Engel, C ; Evans, DG ; Fasching, PA ; Figueroa, J ; Floris, G ; Flyger, H ; Gago-Dominguez, M ; Gapstur, SM ; Garcia-Closas, M ; Gaudet, MM ; Giles, GG ; Goldberg, MS ; Gonzalez-Neira, A ; Guenel, P ; Hahnen, E ; Haiman, CA ; Hakansson, N ; Hall, P ; Hamann, U ; Harrington, PA ; Hart, SN ; Hooning, MJ ; Hopper, JL ; Howell, A ; Hunter, DJ ; Jager, A ; Jakubowska, A ; John, EM ; Kaaks, R ; Keeman, R ; Khusnutdinova, E ; Kitahara, CM ; Kosma, V-M ; Koutros, S ; Kraft, P ; Kristensen, VN ; Kurian, AW ; Lambrechts, D ; Le Marchand, L ; Linet, M ; Lubinski, J ; Mannermaa, A ; Manoukian, S ; Margolin, S ; Martens, JWM ; Mavroudis, D ; Mayes, R ; Meindl, A ; Milne, RL ; Neuhausen, SL ; Nevanlinna, H ; Newman, WG ; Nielsen, SF ; Nordestgaard, BG ; Obi, N ; Olshan, AF ; Olson, JE ; Olsson, H ; Orban, E ; Park-Simon, T-W ; Peterlongo, P ; Plaseska-Karanfilska, D ; Pylkas, K ; Rennert, G ; Rennert, HS ; Ruddy, KJ ; Saloustros, E ; Sandler, DP ; Sawyer, EJ ; Schmutzler, RK ; Scott, C ; Shu, X-O ; Simard, J ; Smichkoska, S ; Sohn, C ; Southey, MC ; Spinelli, JJ ; Stone, J ; Tamimi, RM ; Taylor, JA ; Tollenaar, RAEM ; Tomlinson, I ; Troester, MA ; Truong, T ; Vachon, CM ; van Veen, EM ; Wang, SS ; Weinberg, CR ; Wendt, C ; Wildiers, H ; Winqvist, R ; Wolk, A ; Zheng, W ; Ziogas, A ; Dunning, AM ; Pharoah, PDP ; Easton, DF ; Howie, AF ; Peto, J ; dos-Santos-Silva, I ; Swerdlow, AJ ; Chang-Claude, J ; Schmidt, MK ; Orr, N ; Fletcher, O (SPRINGERNATURE, 2021-02-16)
    BACKGROUND: Epidemiological studies provide strong evidence for a role of endogenous sex hormones in the aetiology of breast cancer. The aim of this analysis was to identify genetic variants that are associated with urinary sex-hormone levels and breast cancer risk. METHODS: We carried out a genome-wide association study of urinary oestrone-3-glucuronide and pregnanediol-3-glucuronide levels in 560 premenopausal women, with additional analysis of progesterone levels in 298 premenopausal women. To test for the association with breast cancer risk, we carried out follow-up genotyping in 90,916 cases and 89,893 controls from the Breast Cancer Association Consortium. All women were of European ancestry. RESULTS: For pregnanediol-3-glucuronide, there were no genome-wide significant associations; for oestrone-3-glucuronide, we identified a single peak mapping to the CYP3A locus, annotated by rs45446698. The minor rs45446698-C allele was associated with lower oestrone-3-glucuronide (-49.2%, 95% CI -56.1% to -41.1%, P = 3.1 × 10-18); in follow-up analyses, rs45446698-C was also associated with lower progesterone (-26.7%, 95% CI -39.4% to -11.6%, P = 0.001) and reduced risk of oestrogen and progesterone receptor-positive breast cancer (OR = 0.86, 95% CI 0.82-0.91, P = 6.9 × 10-8). CONCLUSIONS: The CYP3A7*1C allele is associated with reduced risk of hormone receptor-positive breast cancer possibly mediated via an effect on the metabolism of endogenous sex hormones in premenopausal women.
  • Item
    Thumbnail Image
    A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (vol 12, 1078, 2021)
    Coignard, J ; Lush, M ; Beesley, J ; O'Mara, TA ; Dennis, J ; Tyrer, JP ; Barnes, DR ; McGuffog, L ; Leslie, G ; Bolla, MK ; Adank, MA ; Agata, S ; Ahearn, T ; Aittomaki, K ; Andrulis, IL ; Anton-Culver, H ; Arndt, V ; Arnold, N ; Aronson, KJ ; Arun, BK ; Augustinsson, A ; Azzollini, J ; Barrowdale, D ; Baynes, C ; Becher, H ; Bermisheva, M ; Bernstein, L ; Bialkowska, K ; Blomqvist, C ; Bojesen, SE ; Bonanni, B ; Borg, A ; Brauch, H ; Brenner, H ; Burwinkel, B ; Buys, SS ; Caldes, T ; Caligo, MA ; Campa, D ; Carter, BD ; Castelao, JE ; Chang-Claude, J ; Chanock, SJ ; Chung, WK ; Claes, KBM ; Clarke, CL ; Collee, JM ; Conroy, DM ; Czene, K ; Daly, MB ; Devilee, P ; Diez, O ; Ding, YC ; Domchek, SM ; Doerk, T ; dos-Santos-Silva, I ; Dunning, AM ; Dwek, M ; Eccles, DM ; Eliassen, AH ; Engel, C ; Eriksson, M ; Evans, DG ; Fasching, PA ; Flyger, H ; Fostira, F ; Friedman, E ; Fritschi, L ; Frost, D ; Gago-Dominguez, M ; Gapstur, SM ; Garber, J ; Garcia-Barberan, V ; Garcia-Closas, M ; Garcia-Saenz, JA ; Gaudet, MM ; Gayther, SA ; Gehrig, A ; Georgoulias, V ; Giles, GG ; Godwin, AK ; Goldberg, MS ; Goldgar, DE ; Gonzalez-Neira, A ; Greene, MH ; Guenel, P ; Haeberle, L ; Hahnen, E ; Haiman, CA ; Hakansson, N ; Hall, P ; Hamann, U ; Harrington, PA ; Hart, SN ; He, W ; Hogervorst, FBL ; Hollestelle, A ; Hopper, JL ; Horcasitas, DJ ; Hulick, PJ ; Hunter, DJ ; Imyanitov, EN ; Fox, S ; van der Hout, AH ; Clarke, C ; Jager, A ; Jakubowska, A ; James, PA ; Jensen, UB ; John, EM ; Jones, ME ; Kaaks, R ; Kapoor, PM ; Karlan, BY ; Keeman, R ; Khusnutdinova, E ; Kiiski, JI ; Ko, Y-D ; Kosma, V-M ; Kraft, P ; Kurian, AW ; Laitman, Y ; Lambrechts, D ; Le Marchand, L ; Lester, J ; Lesueur, F ; Lindstrom, T ; Lopez-Fernandez, A ; Loud, JT ; Luccarini, C ; Mannermaa, A ; Manoukian, S ; Margolin, S ; Martens, JWM ; Mebirouk, N ; Meindl, A ; Miller, A ; Milne, RL ; Montagna, M ; Nathanson, KL ; Neuhausen, SL ; Nevanlinna, H ; Nielsen, FC ; O'Brien, KM ; Olopade, OI ; Olson, JE ; Olsson, H ; Osorio, A ; Ottini, L ; Park-Simon, T-W ; Parsons, MT ; Pedersen, IS ; Peshkin, B ; Peterlongo, P ; Peto, J ; Pharoah, PDP ; Phillips, K-A ; Polley, EC ; Poppe, B ; Presneau, N ; Pujana, MA ; Punie, K ; Radice, P ; Rantala, J ; Rashid, MU ; Rennert, G ; Rennert, HS ; Robson, M ; Romero, A ; Rossing, M ; Saloustros, E ; Sandler, DP ; Santella, R ; Scheuner, MT ; Schmidt, MK ; Schmidt, G ; Scott, C ; Sharma, P ; Soucy, P ; Southey, MC ; Spinelli, JJ ; Steinsnyder, Z ; Stone, J ; Stoppa-Lyonnet, D ; Swerdlow, A ; Tamimi, RM ; Tapper, WJ ; Taylor, JA ; Terry, MB ; Teule, A ; Thull, DL ; Tischkowitz, M ; Toland, AE ; Torres, D ; Trainer, AH ; Truong, T ; Tung, N ; Vachon, CM ; Vega, A ; Vijai, J ; Wang, Q ; Wappenschmidt, B ; Weinberg, CR ; Weitzel, JN ; Wendt, C ; Wolk, A ; Yadav, S ; Yang, XR ; Yannoukakos, D ; Zheng, W ; Ziogas, A ; Zorn, KK ; Park, SK ; Thomassen, M ; Offit, K ; Schmutzler, RK ; Couch, FJ ; Simard, J ; Chenevix-Trench, G ; Easton, DF ; Andrieu, N ; Antoniou, AC (NATURE RESEARCH, 2021-05-14)
    Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in general population studies. Other mutation carrier-specific susceptibility variants may exist but studies of mutation carriers have so far been underpowered. We conduct a novel case-only genome-wide association study comparing genotype frequencies between 60,212 general population BC cases and 13,007 cases with BRCA1 or BRCA2 mutations. We identify robust novel associations for 2 variants with BC for BRCA1 and 3 for BRCA2 mutation carriers, P < 10-8, at 5 loci, which are not associated with risk in the general population. They include rs60882887 at 11p11.2 where MADD, SP11 and EIF1, genes previously implicated in BC biology, are predicted as potential targets. These findings will contribute towards customising BC polygenic risk scores for BRCA1 and BRCA2 mutation carriers.
  • Item
    Thumbnail Image
    Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk
    Kapoor, PM ; Mavaddat, N ; Choudhury, PP ; Wilcox, AN ; Lindstrom, S ; Behrens, S ; Michailidou, K ; Dennis, J ; Bolla, MK ; Wang, Q ; Jung, A ; Abu-Ful, Z ; Ahearn, T ; Andrulis, IL ; Anton-Culver, H ; Arndt, V ; Aronson, KJ ; Auer, PL ; Freeman, LEB ; Becher, H ; Beckmann, MW ; Beeghly-Fadiel, A ; Benitez, J ; Bernstein, L ; Bojesen, SE ; Brauch, H ; Brenner, H ; Bruening, T ; Cai, Q ; Campa, D ; Canzian, F ; Carracedo, A ; Carter, BD ; Castelao, JE ; Chanock, SJ ; Chatterjee, N ; Chenevix-Trench, G ; Clarke, CL ; Couch, FJ ; Cox, A ; Cross, SS ; Czene, K ; Dai, JY ; Earp, HS ; Ekici, AB ; Eliassen, AH ; Eriksson, M ; Evans, DG ; Fasching, PA ; Figueroa, J ; Fritschi, L ; Gabrielson, M ; Gago-Dominguez, M ; Gao, C ; Gapstur, SM ; Gaudet, MM ; Giles, GG ; Gonzalez-Neira, A ; Guenel, P ; Haeberle, L ; Haiman, CA ; Hakansson, N ; Hall, P ; Hamann, U ; Hatse, S ; Heyworth, J ; Holleczek, B ; Hoover, RN ; Hopper, JL ; Howell, A ; Hunter, DJ ; John, EM ; Jones, ME ; Kaaks, R ; Keeman, R ; Kitahara, CM ; Ko, Y-D ; Koutros, S ; Kurian, AW ; Lambrechts, D ; Le Marchand, L ; Lee, E ; Lejbkowicz, F ; Linet, M ; Lissowska, J ; Llaneza, A ; MacInnis, RJ ; Martinez, ME ; Maurer, T ; McLean, C ; Neuhausen, SL ; Newman, WG ; Norman, A ; O'Brien, KM ; Olshan, AF ; Olson, JE ; Olsson, H ; Orr, N ; Perou, CM ; Pita, G ; Polley, EC ; Prentice, RL ; Rennert, G ; Rennert, HS ; Ruddy, KJ ; Sandler, DP ; Saunders, C ; Schoemaker, MJ ; Schoettker, B ; Schumacher, F ; Scott, C ; Scott, RJ ; Shu, X-O ; Smeets, A ; Southey, MC ; Spinelli, JJ ; Stone, J ; Swerdlow, AJ ; Tamimi, RM ; Taylor, JA ; Troester, MA ; Vachon, CM ; van Veen, EM ; Wang, X ; Weinberg, CR ; Weltens, C ; Willett, W ; Winham, SJ ; Wolk, A ; Yang, XR ; Zheng, W ; Ziogas, A ; Dunning, AM ; Pharoah, PDP ; Schmidt, MK ; Kraft, P ; Easton, DF ; Milne, RL ; Garcia-Closas, M ; Chang-Claude, J (OXFORD UNIV PRESS INC, 2021-03)
    We evaluated the joint associations between a new 313-variant PRS (PRS313) and questionnaire-based breast cancer risk factors for women of European ancestry, using 72 284 cases and 80 354 controls from the Breast Cancer Association Consortium. Interactions were evaluated using standard logistic regression and a newly developed case-only method for breast cancer risk overall and by estrogen receptor status. After accounting for multiple testing, we did not find evidence that per-standard deviation PRS313 odds ratio differed across strata defined by individual risk factors. Goodness-of-fit tests did not reject the assumption of a multiplicative model between PRS313 and each risk factor. Variation in projected absolute lifetime risk of breast cancer associated with classical risk factors was greater for women with higher genetic risk (PRS313 and family history) and, on average, 17.5% higher in the highest vs lowest deciles of genetic risk. These findings have implications for risk prevention for women at increased risk of breast cancer.
  • Item
    Thumbnail Image
    Assessment of interactions between 205 breast cancer susceptibility loci and 13 established risk factors in relation to breast cancer risk, in the Breast Cancer Association Consortium
    Kapoor, PM ; Lindstrom, S ; Behrens, S ; Wang, X ; Michailidou, K ; Bolla, MK ; Wang, Q ; Dennis, J ; Dunning, AM ; Pharoah, PDP ; Schmidt, MK ; Kraft, P ; Garcia-Closas, M ; Easton, DF ; Milne, RL ; Chang-Claude, J (OXFORD UNIV PRESS, 2020-02)
    BACKGROUND: Previous gene-environment interaction studies of breast cancer risk have provided sparse evidence of interactions. Using the largest available dataset to date, we performed a comprehensive assessment of potential effect modification of 205 common susceptibility variants by 13 established breast cancer risk factors, including replication of previously reported interactions. METHODS: Analyses were performed using 28 176 cases and 32 209 controls genotyped with iCOGS array and 44 109 cases and 48 145 controls genotyped using OncoArray from the Breast Cancer Association Consortium (BCAC). Gene-environment interactions were assessed using unconditional logistic regression and likelihood ratio tests for breast cancer risk overall and by estrogen-receptor (ER) status. Bayesian false discovery probability was used to assess the noteworthiness of the meta-analysed array-specific interactions. RESULTS: Noteworthy evidence of interaction at ≤1% prior probability was observed for three single nucleotide polymorphism (SNP)-risk factor pairs. SNP rs4442975 was associated with a greater reduction of risk of ER-positive breast cancer [odds ratio (OR)int = 0.85 (0.78-0.93), Pint = 2.8 x 10-4] and overall breast cancer [ORint = 0.85 (0.78-0.92), Pint = 7.4 x 10-5) in current users of estrogen-progesterone therapy compared with non-users. This finding was supported by replication using OncoArray data of the previously reported interaction between rs13387042 (r2 = 0.93 with rs4442975) and current estrogen-progesterone therapy for overall disease (Pint = 0.004). The two other interactions suggested stronger associations between SNP rs6596100 and ER-negative breast cancer with increasing parity and younger age at first birth. CONCLUSIONS: Overall, our study does not suggest strong effect modification of common breast cancer susceptibility variants by established risk factors.